2021
17 June, 2021
New article reveals promising results of using FluoGuide’s FG002 technology in guiding surgical removal of cancer
The preclinical study demonstrated FG002 to light up cancer with several promising features holding great promises for the use of guiding...
To the shareholders of FluoGuide A/S The board of directors proposes the election of Mat Thorén as new board member. Mats Thorén...
1 June, 2021
FluoGuide A/S - Flagging message
FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that Arbejdernes Landsbank has informed the Company...
Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 272,700 warrants to employees...
oGuide announc *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The...
The results from the patients in the fifth dose level show, in line with the previous dose levels, that FG001 was well tolerated. The...
The data from the ongoing dose finding trial suggests that background light intensity might be further reduced if FG001 is administered...
The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuilding...
The results from the patients in the fourth dose level show that FG001 was well tolerated, and the light intensity continues to increase...